Clinical Study of Wenluotong lotion combined with compound tripeptide injection in the treatment of peripheral neurotoxicity induced by TP chemotherapy regimen

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068619

Enrollment

Unknown

Registered

2023-02-25

Start date

2023-02-15

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

Control Group: Compound tropicin injection

Treatment Group:Wenluotong lotion combined with compound tripeptide injection

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.NCI-CTCAE grade 1 and above were peripheral neuropathy after treatment with chemotherapy containing TP 2.Age 20-80 years, expected survival of more than 3 months 3.KPS score >=70 4.TCM syndrome differentiation belongs to deficiency of both qi and blood 5.Understand, agree to participate in the study and sign the informed consent

Exclusion criteria

Exclusion criteria: 1.Other causes of peripheral neuropathy that are not caused by chemotherapy drugs 2.Patients who are receiving other medications that may cause neurotoxicity 3.Patients receiving any suspected effective medication, such as anticonvulsants or tricyclic antidepressants 4.Accompanied by hand and foot skin lesions 5.The heart, the liver, the kidney function serious obstacle person 6.Brain metastasis with obvious brain edema or ventricle, brain stem invasion 7.Severe allergy to Taxus or platinum drugs

Design outcomes

Primary

Measure	Time frame
Variable peripheral neuropathy;NRS pain score;Score of TCM syndrome scale;	—

Countries

China

Contacts

Public ContactCai Hui

Fengdu County People's Hospital

94653629@qq.com19922892159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026